Cytek expands Cloud Analysis and Cytek Biosciences stock costs EUR 5.18

Published on 10/02/2026 at 12:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cytek Cloud has more than 28,000 users and adds a Premium tier. Cytek Biosciences stock costs EUR 5.18 on October 2, 2026 after EUR 5.18.

CTKB, US23285D1090, Illustration mit AI erstellt.

Cytek Biosciences (US23285D1090) expanded its Cytek Cloud platform with a new Cloud Analysis tool on September 23, 2026, while Cytek Biosciences stock stood at EUR 5.18 at Lang & Schwarz on October 2, 2026 at 12:44 p.m. CEST, unchanged from the EUR 5.18 prior close. GlobeNewswire reported that the U.S.-available tool extends the workflow from panel design and data acquisition through data analysis.

Cloud platform reaches 28,000 users

The product update gives researchers a way to import experimental data directly from SpectroFlo desktop software and continue analysis in the cloud. Cytek also introduced a Premium subscription tier with cloud-based analysis and online storage, while Basic and Pro plans serve lower levels of functionality.

GlobeNewswire said Cytek Cloud had more than 28,000 users and double-digit year-over-year user growth as of September 23, 2026. That installed base gives the new analysis function a measured commercial angle, because the tool adds a subscription feature to an existing research workflow rather than starting with a new customer platform.

Revenue grows but losses persist

Cytek's second-quarter 2026 revenue rose 6.00 percent year over year to USD 48.10 million, according to The Globe and Mail in its August 5, 2026 earnings-call transcript. The same period produced USD 18.50 million of combined reagent and service revenue, equal to 35.00 percent of revenue over the last 12 months, up from 32.00 percent in the comparable prior-year period.

GAAP gross profit reached USD 28.30 million and the GAAP gross margin was 59.00 percent in the second quarter, but net loss widened to USD 12.20 million from USD 5.60 million a year earlier. Cytek raised the low end of its full-year 2026 revenue guidance to USD 207.00 million from USD 205.00 million, leaving a USD 207.00 million to USD 212.00 million range.

Stock stays within its yearly range

Market data for October 1, 2026 put Cytek's market capitalization at USD 750.3 million and its 52-week range at USD 3.31 to USD 6.18. The unchanged Lang & Schwarz quote leaves the euro reference price between those separately stated Nasdaq levels, while the company's operating profile combines expanding recurring revenue with continuing quarterly losses.